WO2018003900A1 - 栄養状態改善に使用するための組成物 - Google Patents
栄養状態改善に使用するための組成物 Download PDFInfo
- Publication number
- WO2018003900A1 WO2018003900A1 PCT/JP2017/023852 JP2017023852W WO2018003900A1 WO 2018003900 A1 WO2018003900 A1 WO 2018003900A1 JP 2017023852 W JP2017023852 W JP 2017023852W WO 2018003900 A1 WO2018003900 A1 WO 2018003900A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactic acid
- composition
- acid bacteria
- food
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 94
- 230000006872 improvement Effects 0.000 title abstract description 26
- 235000016709 nutrition Nutrition 0.000 title abstract description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 218
- 241000894006 Bacteria Species 0.000 claims abstract description 116
- 239000004310 lactic acid Substances 0.000 claims abstract description 109
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 109
- 210000003205 muscle Anatomy 0.000 claims abstract description 44
- 210000002966 serum Anatomy 0.000 claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 41
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 108010071390 Serum Albumin Proteins 0.000 claims abstract description 29
- 102000007562 Serum Albumin Human genes 0.000 claims abstract description 29
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 239000000047 product Substances 0.000 claims description 68
- 235000013305 food Nutrition 0.000 claims description 51
- 230000008961 swelling Effects 0.000 claims description 33
- 235000003715 nutritional status Nutrition 0.000 claims description 27
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 25
- 235000015872 dietary supplement Nutrition 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 241000186660 Lactobacillus Species 0.000 claims description 7
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 235000015140 cultured milk Nutrition 0.000 claims description 4
- 235000008476 powdered milk Nutrition 0.000 claims description 4
- 235000014347 soups Nutrition 0.000 claims description 4
- 235000013618 yogurt Nutrition 0.000 claims description 4
- 244000294411 Mirabilis expansa Species 0.000 claims description 3
- 235000015429 Mirabilis expansa Nutrition 0.000 claims description 3
- 235000008452 baby food Nutrition 0.000 claims description 3
- 235000013536 miso Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 51
- 206010030113 Oedema Diseases 0.000 abstract description 2
- 229960000448 lactic acid Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 37
- 235000013361 beverage Nutrition 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 102000009027 Albumins Human genes 0.000 description 14
- 108010088751 Albumins Proteins 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- 239000000654 additive Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 9
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 241000186000 Bifidobacterium Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- -1 acidulants Substances 0.000 description 7
- 230000035622 drinking Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 102000018997 Growth Hormone Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 239000000122 growth hormone Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000194033 Enterococcus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000020510 functional beverage Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 241000194036 Lactococcus Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000192132 Leuconostoc Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000192001 Pediococcus Species 0.000 description 3
- 101710129981 Pituitary-specific positive transcription factor 1 Proteins 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 241000202221 Weissella Species 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000020124 milk-based beverage Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000003863 physical function Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186153 Bifidobacterium magnum Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000194029 Enterococcus hirae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 241000186713 Lactobacillus amylovorus Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000509544 Lactobacillus gallinarum Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000577554 Lactobacillus zeae Species 0.000 description 1
- 241000194038 Lactococcus plantarum Species 0.000 description 1
- 241000194037 Lactococcus raffinolactis Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000192129 Leuconostoc lactis Species 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000500340 Pediococcus damnosus Species 0.000 description 1
- 241000191996 Pediococcus pentosaceus Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003270 Vitamin B Chemical group 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 238000012767 chemiluminescent enzyme immunoassay Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000020152 coffee milk drink Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000021121 fermented vegetables Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000006402 liver broth Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Chemical group 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1232—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt in powdered, granulated or dried solid form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
Definitions
- the present invention relates to means and methods for improving nutritional status. Specifically, the present invention relates to a composition for improving serum total protein and / or serum albumin containing lactic acid bacteria and / or a processed product thereof as an active ingredient, a composition for improving swelling, and an increase in muscle mass and / or strength. The present invention relates to a composition for use.
- Serum total protein and serum albumin are used as indicators of nutritional status and are known to decrease with age.
- albumin is an important substance for adjusting the osmotic pressure of blood and causes swelling.
- it is responsible for transporting substances in the body, and humans who are deficient in albumin cannot obtain a sufficient effect of exercise, and it is difficult to maintain muscular strength especially in elderly people.
- albumin deficiency is addressed by administration of albumin preparations and dietary guidance.
- Albumin preparations are expensive and infusion administration, and the burden on patients is large.
- dietary guidance sufficient intake of proteins and amino acids is recommended.
- serum total protein and serum albumin can be improved by improving the decrease in liver function or kidney function.
- Patent Document 1 includes Levenin (registered trademark) (Bifidobacterium Infatis 10 8 cfu, Lactobacillus acidophilus 10 8 cfu and Enterococcus ferricus 10 8 cfu, which are lactic acid bacteria preparations approved as a mixed medicine. has been described to reduce blood indoxyl sulfate, which is one of the causes of chronic renal failure, through the improvement of intestinal flora.
- Patent Document 2 describes that Lactobacillus gasseri CP2305 strain has a vagus nerve activation effect and a stress relieving effect.
- Patent Document 3 describes that the living bacteria of Lactobacillus gasseri strain SBT2055 has a preventive effect / improvement effect on lowering renal function.
- Patent Document 4 describes that dead cells of Lactobacillus gasseri OLL2809 strain are administered to mice to increase the amount of activity and muscle mass.
- the object of the present invention is to provide effective means and methods for improving nutritional status, particularly for middle-aged and elderly subjects and subjects whose nutritional status has deteriorated. Moreover, the objective of this invention is providing the means and method for suppression of the swelling accompanying malnutrition and maintenance and improvement of muscular strength.
- lactic acid bacteria particularly Lactobacillus gasseri
- administration of lactic acid bacteria can improve nutritional status in middle-aged and elderly subjects and those whose nutritional status has deteriorated.
- administration of lactic acid bacteria improves serum total protein and albumin, suppresses swelling, and / or maintains or improves muscle strength and muscle mass.
- the lactic acid bacteria used here can be effective even with dead bacteria.
- the present invention includes, but is not limited to: [1] A composition for improving serum total protein and / or serum albumin containing lactic acid bacteria and / or a processed product thereof as an active ingredient. [2] A swelling improving composition containing lactic acid bacteria and / or a processed product thereof as an active ingredient. [2-1] The composition according to [2], wherein the swelling is a swelling of the triceps surae. [3] A composition for increasing muscle mass and / or strength, comprising lactic acid bacteria and / or a processed product thereof as an active ingredient.
- a lactic acid bacterium belonging to a genus selected from the group consisting of Lactobacillus, Leuconostoc, Lactococcus, Pediococcus, Enterococcus, Bifidobacterium, Streptococcus, and Weissella The composition according to any one of [1] to [3].
- the lactic acid bacterium is Lactobacillus gasseri CP2305 strain (Accession No.
- the food or drink includes a fermented milk drink, yogurt, powdered milk, baby food, miso soup, retort food, and a tablet.
- [12] A method for improving serum total protein and / or serum albumin in a subject, comprising a step of administering lactic acid bacteria and / or a processed product thereof to the subject. [12-1] The method according to [12], wherein the serum total protein and / or serum albumin in the subject is increased compared to a control not administered with the lactic acid bacterium and / or a processed product thereof. [13] A method for improving swelling in a subject, comprising a step of administering lactic acid bacteria and / or a processed product thereof to the subject. [13-1] The method according to [13], wherein the swelling is swelling of the triceps surae.
- a method for improving the nutritional status of a subject comprising administering lactic acid bacteria and / or a processed product thereof to the subject, and improving serum total protein and / or serum albumin in the subject.
- a method for improving the nutritional status of a subject comprising administering lactic acid bacteria and / or a processed product thereof to the subject and improving swelling in the subject.
- a method for improving the nutritional status of a subject comprising administering lactic acid bacteria and / or a processed product thereof to the subject, and increasing muscle mass and / or muscle strength in the subject.
- a composition for improving serum total protein and / or serum albumin a composition for improving swelling, and a composition for increasing muscle mass and / or muscle strength are provided.
- the composition of the present invention is particularly effective for improving nutritional status in middle-aged and elderly people and subjects with poor nutritional status.
- the lactic acid bacteria which are active ingredients are safe and inexpensive, and can be easily ingested as food and drink or nutritional supplements.
- the present invention can improve serum total protein and / or serum albumin, improve swelling, increase muscle mass and / or strength, and improve nutritional status by administration of lactic acid bacteria. Based on knowledge. Specifically, as a result of administering lactic acid bacteria (Lactobacillus gasseri CP2305 strain) to middle-aged and elderly people (40-90s), the effects of improving serum total protein and serum albumin compared to placebo This is based on the fact that the effect of improving the nutritional status of lactic acid bacteria was confirmed.
- the present invention provides a composition for improving serum total protein and / or serum albumin containing lactic acid bacteria and / or a processed product thereof as an active ingredient, a composition for improving swelling, and a composition for increasing muscle mass and / or strength.
- the present invention also includes a method of improving serum total protein and / or serum albumin in a subject, a method of improving swelling in a subject, and a muscle mass and The present invention relates to a method for increasing muscle strength.
- the lactic acid bacteria used in the present invention are bacteria that produce lactic acid from saccharides by fermentation.
- Lactobacillus genus, Leuconostoc genus, Lactococcus genus, Pediococcus pediococcus Bacteria belonging to the genus, Enterococcus genus, Bifidobacterium genus, Streptococcus genus, Weissella genus and the like are included.
- a lactic acid bacterium strain known in the art can be used as long as the lactic acid bacterium or a processed product thereof exhibits a target function or activity specifically described below. In consideration of administration / ingestion to animals, it is preferable that the strain has been confirmed to be safe in animals.
- More specific species of lactic acid bacteria include bacteria belonging to the genus Lactobacillus, Lactobacillus gasseri, Lactobacillus amylovorus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus zeae, Lactobacillus rhamnosus, Lactobacillus Reuteri, Lactobacillus acidophilus, Lactobacillus crispatas, Lactobacillus gallinarum, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus delbrukki Subspecies Bulgaricus, and Lactobacillus johnsonii and so on.
- bacteria belonging to the genus Bifidobacterium include Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium pseudolongum, Bifidobacterium Animalis, Bifidobacterium addressensetis, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium catenatum, Bifidobacterium pseudocatenatum, and Bifidobacterium magnum Is mentioned.
- bacteria belonging to the genus Enterococcus include Enterococcus faecalis, Enterococcus hirae, and Enterococcus faecium.
- bacteria belonging to the genus Streptococcus include Streptococcus thermophilus.
- bacteria belonging to the genus Leuconostoc include Leuconostoc mesenteroides and Leuconostoc lactis.
- bacteria belonging to the genus Lactococcus include Lactococcus lactis, Lactococcus plantarum, and Lactococcus raffinolactis.
- bacteria belonging to the genus Pediococcus examples include Pediococcus pentosaceus and Pediococcus damnosus.
- the bacteria belonging to the genus Weisella include: Weisera Chibaria, Weisera Confuser, Weisera Halo Tolerance, Weisera Helenica, Weisera Kandreri, Weisera Kimchii, Weisera Coleensis, Weisera Minol, Weisella Paramesenteroides, Weisera Sori, Weisera Tyrandensis, and Weisera Virides Sense.
- the intended function or activity in the context of the present invention means the action of improving serum total protein and / or serum albumin in a subject.
- “Improvement” in this case means an increase in serum total protein and / or serum albumin, normal value of serum total protein and / or serum albumin (for example, 6.5 to 8.3 g / dL and 3.5 to 5.2 g / dL, respectively) As well as preventing the reduction of serum total protein and / or serum albumin.
- Serum total protein and serum albumin can be measured by any method known in the art.
- the intended function or activity in relation to the present invention means an effect of improving swelling.
- Swelling refers to a condition in which the body's water has increased abnormally, and is a symptom that occurs throughout the body, including the face, limbs, and internal organs. “Improvement” in this case refers to suppression of swelling and reduction of occurrence of swelling. Swelling can be measured by any method known in the art, such as a change in the circumference of the triceps surae muscle, a change in the circumference of the ankle, or a time change in the depression after compression in the lower knee. can do.
- the intended function or activity in the context of the present invention means an increase in muscle mass and / or strength.
- “Increase” in this case means not only an increase in muscle mass and / or muscle strength, but also a prevention of a decrease in muscle mass and / or muscle strength.
- the increase in muscle mass is measured by measuring factors related to muscle (growth hormone, insulin-like growth factor 1 (IGF-1), etc.), and the increase in muscle strength is measured by measuring the gastrocnemius circumference or grip strength, for example. Can be determined.
- the target function or activity means an effect of improving nutritional status.
- Improvement of nutritional status means that metabolism for maintaining energy and structure necessary for activities in maintaining physical functions is maintained normally.
- the nutritional state can be improved by increasing blood hemoglobin, for example by increasing serum total albumin and / or serum total protein.
- Deterioration of nutritional status refers to a state in which the metabolism required to maintain the energy and structure necessary to maintain physical function is not maintained normally, for example, serum total protein is 6.5 g / dL or less and / or When the serum albumin is 3.5 g / dL or 4 g / dL or less, the subject can be determined to have a poor nutritional state or low even when normal.
- any lactic acid bacterium can be used as long as the microbial cell or the processed product is evaluated to have the target function or activity by the method described above.
- Preferred lactic acid bacteria having such a function or activity include the Lactobacillus gasseri CP2305 strain and the Lactobacillus gasseri CP2305s strain.
- the Lactobacillus gasseri CP2305 strain was obtained by the applicant from the National Institute of Advanced Industrial Science and Technology (Ibaraki Prefecture, Japan), an independent administrative agency that is an international depositary authority based on the provisions of the Budapest Treaty for the deposit of patent microorganisms.
- mutant strains of the specific strains described above can also be used as long as they have the intended function or activity.
- the Lactobacillus gasseri CP2305s strain is a mutant obtained from the Lactobacillus gasseri CP2305 strain, and the mutants of the CP2305 strain and the CP2305s strain are also likely to have the desired function or activity in the same manner.
- Such mutant strains can also be used in the present invention.
- mutant strain means any strain obtained from the parent strain. Specifically, it is obtained by a method of artificially increasing the frequency of mutation from a parent strain by natural mutation or induced mutation by a chemical or physical mutagen, or by a specific mutagenesis technique (for example, gene recombination). Means a stock. A microbial individual produced by such a method is repeatedly selected and separated, and a useful microbial individual is bred to obtain a mutant having the desired function or activity.
- mutant strains derived from Lactobacillus gasseri CP2305 strain or CP2305s strain can be easily distinguished from other lactic acid strains by molecular weight distribution of amplified fragments of lactic acid bacteria genomic DNA by polymerase chain reaction (PCR) method.
- PCR polymerase chain reaction
- a DNA sample is prepared, and gene amplification is performed by PCR using primers having a characteristic sequence (for example, 16S rDNA base sequence). It is possible to determine whether or not it is a mutant strain derived from the CP2305 strain or the CP2305s strain.
- the method for confirming whether or not it is a mutant is not limited to this method, and it can be confirmed whether or not it is a mutant by a technique known in the art such as mycological properties. .
- Lactic acid bacteria can be prepared by culturing under appropriate conditions using a medium usually used for culturing lactic acid bacteria.
- a medium usually used for culturing lactic acid bacteria contains a carbon source, a nitrogen source, inorganic salts, and the like and can culture lactic acid bacteria efficiently, either a natural medium or a synthetic medium may be used. If so, a known medium suitable for the strain to be used can be appropriately selected. Lactose, glucose, sucrose, fructose, galactose, molasses etc. can be used as carbon source, and organic nitrogen containing casein hydrolyzate, whey protein hydrolyzate, soy protein hydrolyzate etc. as nitrogen source Things can be used.
- inorganic salts phosphates, sodium, potassium, magnesium and the like can be used.
- a medium suitable for culturing lactic acid bacteria include MRS liquid medium, GAM medium, BL medium, Briggs Liver Broth, animal milk, skim milk, and milky whey.
- a sterilized MRS medium can be used.
- lactic acid bacteria are cultured at 20 to 50 ° C., preferably 25 to 42 ° C., more preferably about 37 ° C. under anaerobic conditions.
- the temperature condition can be adjusted by a thermostatic bath, a mantle heater, a jacket, or the like.
- the anaerobic condition means a low oxygen environment in which lactic acid bacteria can grow.
- an anaerobic chamber, an anaerobic box, a sealed container or bag containing an oxygen scavenger, or the like is used.
- Anaerobic conditions can be achieved by sealing the culture vessel.
- the culture format is stationary culture, shake culture, tank culture, or the like.
- the culture time can be 3 to 96 hours.
- the pH of the medium at the start of the culture is preferably maintained at 4.0 to 8.0.
- lactic acid bacteria A specific preparation example of lactic acid bacteria will be briefly described.
- the lactic acid bacterium is inoculated in a medium for lactic acid bacteria (for example, MRS liquid medium), preferably a medium for food grade lactic acid bacteria, and is overnight at about 37 ° C. ( Incubate for about 18 hours.
- a medium for lactic acid bacteria for example, MRS liquid medium
- MRS liquid medium preferably a medium for food grade lactic acid bacteria
- the obtained lactic acid bacteria culture may be used as it is, or may be subjected to solid-liquid separation and / or sterilization by filtration and / or filtration if necessary.
- the lactic acid bacteria used in the present invention may be live cells or dead cells, may be wet cells, or may be dry cells. Preferably, dead lactic acid bacteria are used.
- a processed product of lactic acid bacteria obtained by processing microbial cells of lactic acid bacteria may be used, or a processed product of lactic acid bacteria may be further processed.
- An example of such processing is described below.
- It can be prepared as a suspension or dilution by suspending or diluting lactic acid bacteria and / or treated products in an appropriate solvent.
- solvent examples include water, physiological saline, phosphate buffered saline (PBS), and the like.
- a fermented product can be prepared by fermenting raw milk, skim milk powder or soy milk using lactic acid bacteria cells and / or processed products.
- lactic acid bacteria or other treated lactic acid bacteria are inoculated into raw milk, skim milk powder or soy milk, and fermented under lactic acid bacteria fermentation conditions known in the art (substantially the same as the lactic acid bacteria culture conditions described above).
- the obtained fermentation product may be used as it is, or may be subjected to other treatments such as filtration, sterilization, dilution and concentration.
- Lactic acid bacteria and / or treated products can be prepared as a sterilized product by sterilization.
- known sterilization processes such as filtration sterilization, radioactive sterilization, heating sterilization, and pressure sterilization can be performed.
- the lactic acid bacteria and / or the treated product are treated at a high temperature (for example, 80 to 150 ° C.) for a certain period of time, for example, about 10 minutes to 1 hour (for example, about 10 to 20 minutes). .
- a high temperature for example, 80 to 150 ° C.
- a certain period of time for example, about 10 minutes to 1 hour (for example, about 10 to 20 minutes).
- a crushed product and a cell-free extract can be prepared.
- crushing can be performed by physical crushing (stirring, filter filtration, etc.), enzyme dissolution treatment, chemical treatment, or autolysis treatment.
- Extracts can be obtained by extracting lactic acid bacterial cells and / or processed products using an appropriate aqueous or organic solvent.
- the extraction method is not particularly limited as long as it is an extraction method using an aqueous solvent or an organic solvent as an extraction solvent, but the lactic acid bacterium or a processed product obtained by performing other treatments on the lactic acid bacterium is treated with an aqueous or organic solvent (for example, water, methanol). And a known method such as a method of immersing, stirring or refluxing in ethanol).
- the lactic acid bacteria cells and / or the treated product can be dried to obtain a powdery product (powder) or a granular product.
- a powdery product for example, spray drying, drum drying, vacuum drying, freeze-drying etc. are mentioned, These can be employ
- components or fractions having the desired function or activity may be purified from lactic acid bacteria and / or processed products using a known separation / purification method.
- separation / purification methods include methods utilizing solubility such as salt precipitation and organic solvent precipitation, methods utilizing differences in molecular weight such as dialysis, ultrafiltration and gel filtration, and ion exchange chromatography. Examples include methods that use the difference in charge, methods that use specific binding such as affinity chromatography, and methods that use hydrophobicity such as hydrophobic chromatography and reverse phase chromatography. Or two or more types can be used in combination.
- the lactic acid bacteria and / or processed product obtained above are used alone or in combination with other components as a composition of the present invention or in a food, drink, feed, nutritional supplement or pharmaceutical composition.
- Ingestion is expected to have an effect of improving serum total protein and / or serum albumin, an effect of improving swelling, or an effect of increasing muscle mass and / or muscular strength, and thereby an improvement in nutritional status.
- composition of the present invention contains the above-mentioned lactic acid bacteria and / or treated product as an active ingredient, but may contain one kind of lactic acid bacteria and / or treated product, or a plurality of different lactic acid bacteria.
- a body and / or a processed product, and a plurality of processed lactic acid bacteria processed differently may be included in combination.
- composition of the present invention includes additives, other known drugs, and nutritional supplements described below, unless the target function or action is inhibited. You may add an agent etc. individually or in combination of two or more.
- composition of the present invention is not particularly limited, and examples thereof include tablets, capsules, granules, powders, powders, syrups, dry syrups, liquids, suspensions, inhalants and other oral preparations, suppositories, and the like. It is good also as dosage forms, such as an enteral formulation, a drip, an injection. Of these, oral preparations are preferred. Liquid preparations such as liquids and suspensions may be dissolved or suspended in water or other appropriate medium immediately before taking. In the case of tablets and granules, the preparations may be prepared by well-known methods. The surface may be coated. Furthermore, the composition of the present invention may be a controlled release formulation such as sustained release formulation, delayed release formulation or immediate release formulation using techniques known in the art.
- Such a dosage form composition comprises the above-mentioned components, commonly used excipients, disintegrants, binders, wetting agents, stabilizers, buffers, lubricants, preservatives, surfactants, sweeteners.
- Additives such as flavoring agents, fragrances, acidulants, and coloring agents can be blended according to the dosage form, and can be produced according to conventional methods.
- a pharmaceutically acceptable carrier or additive can be blended.
- Such pharmaceutically acceptable carriers and additives include water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer, sodium alginate, water soluble dextran, water soluble dextrin , Sodium carboxymethyl starch, pectin, xanthan gum, gum arabic, casein, gelatin, agar, glycerin, propylene glycol, polyethylene glycol, petrolatum, paraffin, stearyl alcohol, stearic acid, human serum albumin, mannitol, sorbitol, lactose, pharmaceutical additives
- an artificial cell structure such as a liposome can be used.
- the content of lactic acid bacteria and / or treated products as active ingredients varies depending on the dosage form, but the amount of lactic acid bacteria is usually Is in the range of 0.0001 to 99% by mass, preferably 0.001 to 80% by mass, more preferably 0.001 to 75% by mass, and the dosage per day can be controlled so that the desired intake of the active ingredient can be ingested. It is desirable to make it.
- the number of lactic acid bacteria or treated products contained in the composition of the present invention is about 10 7 / g to about 10 12 / g (in the case of treated products, the number of lactic acid bacteria before treatment).
- drugs that can be added or blended in the composition of the present invention include, but are not limited to, taurine, coenzyme Q, polyphenols, catechins, animal proteins, milk proteins, vegetable proteins and the like. Can be mentioned.
- various additives and other various substances used in the production of pharmaceuticals, foods and drinks, and feeds may coexist in the composition of the present invention.
- Such substances and additives include various fats and oils (for example, vegetable oils such as soybean oil, corn oil, safflower oil, olive oil, animal fats such as beef tallow and sardine oil), herbal medicines (eg royal jelly, carrots, etc.), Amino acids (eg, glutamine, cysteine, leucine, arginine, etc.), polyhydric alcohols (eg, ethylene glycol, polyethylene glycol, propylene glycol, glycerin, sugar alcohols such as sorbitol, erythritol, xylitol, maltitol, mannitol, etc.), natural polymers (For example, gum arabic, agar, water-soluble corn fiber, gelatin, xanthan gum, casein, gluten or gluten hydrolyzate, lecithin, starch, dextrin, etc
- the amount of these additives is appropriately determined according to the type of additive and the amount of intake to be desired, but the content of lactic acid bacteria and / or processed products as active ingredients varies depending on the dosage form.
- the amount of lactic acid bacteria before the treatment is usually preferably 0.0001 to 99% by mass, preferably 0.001 to 80% by mass, more preferably 0.001 to 75% by mass. .
- Subjects to be administered or ingested the composition of the present invention are vertebrates, specifically mammals such as humans, primates (monkeys, chimpanzees, etc.), livestock animals (bovines, horses, pigs, sheep, chickens, etc.). , Pet animals (dogs, cats, etc.), laboratory animals (mouse, rats, etc.), reptiles and birds.
- subjects whose nutritional status is desired to be improved such as middle-aged people (eg 40 years of age or older), humans whose nutritional status has deteriorated or decreased (eg serum total protein below about 6.5 g / dL, and / or Or, a human whose serum albumin is about 4 g / dL or less is preferred as a subject.
- Administration or intake of the composition of the present invention is the age and weight of the subject, administration / intake route, administration / ingestion frequency, administration purpose (improving nutritional status, serum total protein / albumin improvement, swelling improvement, muscle mass / muscle strength increase) Etc.) and can be changed within a wide range at the discretion of those skilled in the art so as to achieve the intended action.
- the lactic acid bacteria and / or processed product contained in the composition is usually about 10 6 to about 10 12 per kg body weight as the amount of lactic acid bacteria, preferably It is desirable to administer about 10 7 to about 10 11 .
- the content ratio of the lactic acid bacteria and / or the processed product is not particularly limited, and may be appropriately adjusted according to the ease of production, the preferable daily dose, and the like. Since the composition of the present invention is highly safe, the intake can be further increased. The daily intake may be taken once, but may be taken in several divided doses. In addition, the frequency of administration or ingestion is not particularly limited, and the administration / intake route, the age and weight of the subject, and the intended effect (improvement of nutritional status, improvement of serum total protein / albumin, improvement of swelling, increase in muscle mass / muscle strength) Etc.) can be appropriately selected according to various conditions.
- the administration / intake route of the composition of the present invention is not particularly limited, and includes oral administration or ingestion, parenteral administration (eg, rectal, subcutaneous, intramuscular, intravenous administration) and the like.
- the composition of the present invention is particularly preferably administered or ingested orally.
- the composition of the present invention improves serum total protein and / or serum albumin, possibly by improving the decrease in liver function or kidney function, and can effectively cope with the decrease due to aging in particular. Specifically, the serum total protein and / or serum albumin in the subject is increased compared to a control not administered with the composition of the present invention (lactic acid bacteria and / or processed product thereof).
- the composition of the present invention also improves swelling or increases muscle mass and / or strength. Specifically, the swelling in the subject is reduced or the muscle mass and / or the muscle strength is increased in the subject as compared with a control not administered with the composition of the present invention (lactic acid bacteria and / or processed product thereof). Therefore, the composition of the present invention has an effect of improving nutritional status in subjects, particularly middle-aged and elderly people and subjects whose nutritional status has deteriorated.
- composition of the present invention may be used in combination with other medicines, treatment or prevention methods.
- Such other medicaments may form one preparation with the composition of the present invention, or may be administered in separate preparations at the same time or at intervals.
- composition of the present invention can be used as a pharmaceutical composition to improve serum total protein / serum albumin, improve swelling, increase muscle mass / muscle strength, improve nutritional status, and the like.
- the composition of the present invention is highly safe and easy to take for a long time. Therefore, the composition of this invention can be used also for food-drinks, a nutritional supplement, and feed.
- the composition of the present invention has the functions or activities as described above, and contains lactic acid bacteria having a dietary experience, and has high safety. Furthermore, since it does not inhibit the flavor of the food and drink itself even if added to various foods and drinks, it can be added to various foods and drinks and continuously consumed, and the intended function or action is expected to be exhibited.
- the food and drink of the present invention contains the above-described composition of the present invention.
- drinks are also included in the food and drink.
- the food / beverage products containing the composition of the present invention include a functional food / beverage product (nutritional supplement) that promotes health through functions and activities such as nutritional status improvement, serum total protein / albumin improvement, swelling improvement, muscle mass / muscle strength increase, etc.
- a functional food / beverage product nutritional supplement
- all foods and beverages that can contain the composition of the present invention are included.
- the “functional food / beverage” of the present invention means a food / beverage having a certain functionality with respect to a living body, for example, a health functional food / beverage including a specific health food and a nutritional functional food, a functional indication food, a special food So-called health foods and drinks such as foods, nutritional supplements, health supplements and foods, supplements (for example, various dosage forms such as tablets, coated tablets, dragees, capsules and liquids) and beauty foods and drinks (for example, diet foods and drinks) Includes all.
- the functional food / beverage products of the present invention also include health food / beverage products to which health claims based on the food standards of Codex (FAO / WHO Joint Food Standards Committee) are applied.
- foods and drinks include liquid foods such as tube enteral nutrients, healthy foods and drinks in the form of preparations such as tablet confections, tablets, chewable tablets, tablets, powders, powders, capsules, granules and drinks, and Nutritional supplement food and drink; tea beverages such as green tea, oolong tea and black tea, soft drinks, jelly drinks, sports drinks, milk drinks, carbonated drinks, vegetable drinks, fruit juice drinks, fermented vegetable drinks, fermented fruit drinks, fermented milk drinks (yogurt, etc.) ), Lactic acid bacteria beverages, milk beverages (coffee milk, fruit milk, etc.), powdered beverages (milk powder, etc.), cocoa beverages, milk and beverages such as purified water; spreads such as butter, jam, sprinkles and margarine; mayonnaise, shortening, Custard cream, dressing, bread, cooked rice, noodles, pasta, miso soup, tofu, yogurt, baby food, soup or Sauces, confectionery products (for example, biscuits and cookies such, chocolate, candy, cake, ice cream,
- the food and drink according to the present invention include other food materials, various nutrients, various vitamins, minerals, dietary fiber, and various additives (for example, taste ingredients, sweet tastes) used in the production of the food and drink.
- various additives for example, taste ingredients, sweet tastes
- sour agents such as organic acids, stabilizers, flavors
- the blending amount of lactic acid bacteria which are active ingredients and / or processed products thereof can be appropriately determined by those skilled in the art in consideration of the form of the food / beverage products and the required taste or texture.
- the total amount of lactic acid bacteria and / or processed product in the composition to be added is 0.0001 to 99% by mass, preferably 0.001 to 80% by mass, more preferably 0.001 to 75% by mass as the amount of lactic acid bacteria.
- the blending amount is as follows. Since the composition of the present invention is highly safe, the blending amount in food and drink can be further increased. It is preferable that the daily intake can be controlled so that the desired intake can be eaten and consumed.
- the composition of the present invention may be contained in a food or drink by any appropriate method available to those skilled in the art. For example, after preparing the composition of this invention in the liquid form, the gel form, the solid form, the powder form, or the granular form, it can be mix
- the composition of the present invention may be applied, coated, penetrated or sprayed on food and drink.
- the composition of this invention may be disperse
- the composition of the present invention may be wrapped with an edible film or an edible coating agent.
- composition of this invention after adding a suitable excipient
- the food / beverage products containing the composition of the present invention may be further processed, and such processed products are also included in the scope of the present invention.
- the food and drink of the present invention have a useful effect and are highly safe and have no side effects.
- the composition of the present invention has a good flavor, and even when added to various foods and drinks, it does not inhibit the taste of the food or drink. Useful effects are expected.
- composition of the present invention can be blended not only in foods and drinks for humans, but also in animal feeds for livestock (cattle, pigs, chickens, etc.), racehorses, pets (dogs, cats, etc.). Since the feed is almost the same as the food and drink except that the subject is other than a human, the above description regarding the food and drink can be applied to the feed as well.
- IGF-1 insulin-like growth factor 1
- Example 1 ⁇ Preparation of test beverage> Lactobacillus gasseri CP2305 strain and Lactobacillus helveticus were used to ferment skim milk powder and yeast extract at 32-37 ° C for 12-22 hours, and then the resulting fermented milk was liquid sugar, sweetener, acidulant , Formulated and sterilized with stabilizers and fragrances.
- the placebo was prepared and sterilized in the same manner as described above using milk fermented under the same conditions using Lactobacillus helveticus without using CP2305 strain. 200 ml of a sterilizing solution was filled in a paper container to obtain a test beverage and a placebo beverage.
- Example 2 ⁇ Human drinking test> Divided into 2 groups for 34 middle-aged and elderly people (40-90s), test beverages containing 10 or 10 Lactobacillus gasseri CP2305 strains, or placebo beverages not containing CP2305 strains 1 dose per day for 12 weeks.
- FIG. 3 shows the change in the circumference of the triceps surae muscle with respect to the drinking time (weeks).
- IGF-1 insulin-like growth factor 1
- FIGS. 4 and 5 show changes in growth hormone and IGF-1 with respect to drinking time (weeks), respectively.
- 6 and 7 plot changes with respect to respective initial values, and a regression line was obtained by a least square method.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pediatric Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Fodder In General (AREA)
- Dairy Products (AREA)
Abstract
Description
特許文献3には、ラクトバチルス・ガセリSBT2055株の生菌に腎機能低下予防効果・改善効果がある旨が記載されている。
特許文献4には、ラクトバチルス・ガセリOLL2809株の死菌体をマウスに投与し、活動量と筋肉量が増加することが記載されている。
[1] 乳酸菌及び/又はその処理物を有効成分として含有する血清総タンパク質及び/又は血清アルブミンの改善用組成物。
[2] 乳酸菌及び/又はその処理物を有効成分として含有するむくみ改善用組成物。
[2-1] むくみが下腿三頭筋のむくみである、[2]に記載の組成物。
[3] 乳酸菌及び/又はその処理物を有効成分として含有する筋肉量及び/又は筋力増加用組成物。
[4] 乳酸菌がラクトバチルス属、ロイコノストック属、ラクトコッカス属、ペディオコッカス属、エンテロコッカス属、ビフィドバクテリウム属、ストレプトコッカス属、及びワイセラ属からなる群より選択される属に属する乳酸菌である、[1]~[3]のいずれかに記載の組成物。
[5] 乳酸菌がラクトバチルス・ガセリである、[1]~[4]のいずれかに記載の組成物。
[6] 乳酸菌が、ラクトバチルス・ガセリCP2305株(受託番号FERM BP-11331)若しくはその変異株、又はラクトバチルス・ガセリCP2305s株(受託番号NITE BP-1405)若しくはその変異株である、[1]~[5]のいずれかに記載の組成物。
[6-1] 乳酸菌が死菌体である、[1]~[6]のいずれかに記載の組成物。
[7] 栄養状態改善に使用するための、[1]~[6]のいずれかに記載の組成物。
[8] 投与対象が40歳以上のヒト対象である、[1]~[7]のいずれかに記載の組成物。
[9] 投与対象が、血清総タンパク質6.5g/dL以下、及び/又は血清アルブミン4g/dL以下のヒト対象である、[1]~[8]のいずれかに記載の組成物。
[10] 組成物が、飲食品、飼料、栄養補助剤及び医薬からなる群より選択される、[1]~[9]のいずれかに記載の組成物。
[11] 飲食品が、発酵乳飲料、ヨーグルト、粉ミルク、ベビーフード、味噌汁、レトルト食品及びタブレットを含む、[10]に記載の組成物。
[12-1] 上記乳酸菌及び/又はその処理物を投与していない対照と比較して、上記対象における血清総タンパク質及び/又は血清アルブミンを増加させる、[12]に記載の方法。
[13] 乳酸菌及び/又はその処理物を対象に投与するステップを含む、対象においてむくみを改善する方法。
[13-1] むくみが下腿三頭筋のむくみである、[13]に記載の方法。
[13-2] 上記乳酸菌及び/又はその処理物を投与していない対照と比較して、上記対象におけるむくみを低下させる、[13]に記載の方法。
[14] 乳酸菌及び/又はその処理物を対象に投与するステップを含む、対象において筋肉量及び/又は筋力を増加させる方法。
[14-1] 上記乳酸菌及び/又はその処理物を投与していない対照と比較して、上記対象における筋肉量及び/又は筋力を増加させる、[14]に記載の方法。
[15] 乳酸菌及び/又はその処理物を対象に投与し、対象において血清総タンパク質及び/又は血清アルブミンを改善するステップを含む、対象の栄養状態を改善する方法。
[16] 乳酸菌及び/又はその処理物を対象に投与し、対象においてむくみを改善するステップを含む、対象の栄養状態を改善する方法。
[17] 乳酸菌及び/又はその処理物を対象に投与し、対象において筋肉量及び/又は筋力を増加させるステップを含む、対象の栄養状態を改善する方法。
(1)乳酸菌の準備
乳酸菌として、ラクトバチルス・ガセリCP2305株(受託番号FERM BP-11331)及びラクトバチルス・ガセリCP2305s株(受託番号NITE BP-1405)を準備した。
対象から採血したスピッツを転倒混和、静置後、遠心分離を行い、血清を採取した。得られた血清を比色法(Biuret法)及び比色法(BCP改良法)にて血清総タンパク質及びアルブミンを測定した。
対象の下腿三頭筋を周囲長計測メジャーを用いて測定した。
対象からの血清を用いて、CLEIA法(化学発光酵素免疫測定法)にて成長ホルモンを測定した。血清を用いて、RIA法にてIGF-1を測定した。
対象の腓腹筋を周囲長計測メジャーを用いて測定した。
握力計を用いて握力を測定した。
<試験飲料の調製>
ラクトバチルス・ガセリCP2305株及びラクトバチルス・ヘルベティカスを用いて、脱脂粉乳及び酵母エキスを、32~37℃にて12~22時間発酵した後、得られた発酵乳に液糖、甘味料、酸味料、安定剤、香料で調合・殺菌した。
また、プラセボは、CP2305株を使用せずにラクトバチルス・ヘルベティカスを用いて同条件にて発酵した乳を用いて、上記と同様に調合・殺菌した。
殺菌液を紙容器に200ml充填し、試験飲料及びプラセボ飲料とした。
<ヒト飲用試験>
中高齢者(40~90歳代)34名を対象として2群に分け、ラクトバチルス・ガセリCP2305株を含有した試験飲料(菌体量として1010個)、又はCP2305株を含まないプラセボ飲料を、1日1本で12週間にわたり投与した。
受託番号NITE BP-1405(ラクトバチルス・ガセリCP2305s株、2012年8月14日付寄託)
Claims (11)
- 乳酸菌及び/又はその処理物を有効成分として含有する血清総タンパク質及び/又は血清アルブミンの改善用組成物。
- 乳酸菌及び/又はその処理物を有効成分として含有するむくみ改善用組成物。
- 乳酸菌及び/又はその処理物を有効成分として含有する筋肉量及び/又は筋力増加用組成物。
- 乳酸菌がラクトバチルス属に属する乳酸菌である、請求項1~3のいずれか1項に記載の組成物。
- 乳酸菌がラクトバチルス・ガセリである、請求項1~4のいずれか1項に記載の組成物。
- 乳酸菌が、ラクトバチルス・ガセリCP2305株(受託番号FERM BP-11331)若しくはその変異株、又はラクトバチルス・ガセリCP2305s株(受託番号NITE BP-1405)若しくはその変異株である、請求項1~5のいずれか1項に記載の組成物。
- 栄養状態改善に使用するための、請求項1~6のいずれか1項に記載の組成物。
- 投与対象が40歳以上のヒト対象である、請求項1~7のいずれか1項に記載の組成物。
- 投与対象が、血清総タンパク質6.5g/dL以下、及び/又は血清アルブミン4g/dL以下のヒト対象である、請求項1~8のいずれか1項に記載の組成物。
- 組成物が、飲食品、飼料、栄養補助剤及び医薬からなる群より選択される、請求項1~9のいずれか1項に記載の組成物。
- 飲食品が、発酵乳飲料、ヨーグルト、粉ミルク、ベビーフード、味噌汁、レトルト食品及びタブレットを含む、請求項10に記載の組成物。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017287989A AU2017287989B2 (en) | 2016-06-30 | 2017-06-29 | Composition for use in improvement of nutritional state |
JP2018525244A JP6923883B2 (ja) | 2016-06-30 | 2017-06-29 | 栄養状態改善に使用するための組成物 |
EP17820254.5A EP3479835A4 (en) | 2016-06-30 | 2017-06-29 | COMPOSITION FOR USE IN IMPROVING THE NUTRITIONAL STATE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016130814 | 2016-06-30 | ||
JP2016-130814 | 2016-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018003900A1 true WO2018003900A1 (ja) | 2018-01-04 |
Family
ID=60787090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/023852 WO2018003900A1 (ja) | 2016-06-30 | 2017-06-29 | 栄養状態改善に使用するための組成物 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3479835A4 (ja) |
JP (1) | JP6923883B2 (ja) |
AU (1) | AU2017287989B2 (ja) |
WO (1) | WO2018003900A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019230957A1 (ja) * | 2018-06-01 | 2019-12-05 | 雪印メグミルク株式会社 | 筋修復促進用組成物 |
JP2021042142A (ja) * | 2019-09-06 | 2021-03-18 | 森永乳業株式会社 | 筋肉量及び/又は筋力の維持、或いは筋肉量及び/又は筋力の低下抑制用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物 |
WO2022065330A1 (ja) * | 2020-09-23 | 2022-03-31 | 雪印メグミルク株式会社 | 筋委縮予防剤 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020289102A1 (en) * | 2019-06-03 | 2022-01-20 | Asahi Group Holdings, Ltd. | Walking ability improver |
TWI783780B (zh) * | 2021-11-16 | 2022-11-11 | 葡萄王生技股份有限公司 | 戊醣片球菌gkp4用於製備改善肌少症之口服組成物的用途 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09110707A (ja) | 1995-10-12 | 1997-04-28 | Wakamoto Pharmaceut Co Ltd | 慢性腎不全改善剤および透析患者のクオリティー オブ ライフ改善剤 |
JP2007039423A (ja) * | 2004-12-24 | 2007-02-15 | Meiji Milk Prod Co Ltd | 皮膚改善用及び/又は治療用の発酵乳とその製造方法 |
JP2012017282A (ja) | 2010-07-07 | 2012-01-26 | Calpis Co Ltd | 迷走神経活性化剤 |
WO2013031749A1 (ja) | 2011-08-29 | 2013-03-07 | 株式会社明治 | 身体活動を促進させる乳酸菌 |
JP2014055195A (ja) | 2013-12-26 | 2014-03-27 | Snow Brand Milk Products Co Ltd | 加齢に伴う代謝異常症の予防・改善・治療剤 |
JP2014113137A (ja) * | 2012-11-16 | 2014-06-26 | Calpis Co Ltd | 新規の低温耐性ラクトバチルス・ガセリ株 |
WO2014132982A1 (ja) * | 2013-02-27 | 2014-09-04 | 株式会社明治 | ストレス軽減剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140322172A1 (en) * | 2011-12-07 | 2014-10-30 | Calpis Co., Ltd. | Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof |
JP6053466B2 (ja) * | 2012-11-16 | 2016-12-27 | アサヒグループホールディングス株式会社 | ストレス性下痢の抑制剤 |
JP5950993B2 (ja) * | 2014-12-25 | 2016-07-13 | アサヒグループホールディングス株式会社 | 迷走神経活性化剤 |
JP6894096B2 (ja) * | 2016-06-30 | 2021-06-23 | アサヒグループホールディングス株式会社 | 軟骨再生促進用組成物 |
AU2017287988A1 (en) * | 2016-06-30 | 2019-02-21 | Asahi Group Holdings, Ltd. | Renal anemia ameliorating composition |
-
2017
- 2017-06-29 WO PCT/JP2017/023852 patent/WO2018003900A1/ja unknown
- 2017-06-29 JP JP2018525244A patent/JP6923883B2/ja active Active
- 2017-06-29 EP EP17820254.5A patent/EP3479835A4/en not_active Withdrawn
- 2017-06-29 AU AU2017287989A patent/AU2017287989B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09110707A (ja) | 1995-10-12 | 1997-04-28 | Wakamoto Pharmaceut Co Ltd | 慢性腎不全改善剤および透析患者のクオリティー オブ ライフ改善剤 |
JP2007039423A (ja) * | 2004-12-24 | 2007-02-15 | Meiji Milk Prod Co Ltd | 皮膚改善用及び/又は治療用の発酵乳とその製造方法 |
JP2012017282A (ja) | 2010-07-07 | 2012-01-26 | Calpis Co Ltd | 迷走神経活性化剤 |
WO2013031749A1 (ja) | 2011-08-29 | 2013-03-07 | 株式会社明治 | 身体活動を促進させる乳酸菌 |
JP2014113137A (ja) * | 2012-11-16 | 2014-06-26 | Calpis Co Ltd | 新規の低温耐性ラクトバチルス・ガセリ株 |
WO2014132982A1 (ja) * | 2013-02-27 | 2014-09-04 | 株式会社明治 | ストレス軽減剤 |
JP2014055195A (ja) | 2013-12-26 | 2014-03-27 | Snow Brand Milk Products Co Ltd | 加齢に伴う代謝異常症の予防・改善・治療剤 |
Non-Patent Citations (3)
Title |
---|
"Chonai Nyusankin Enterococcus-kin no Yuyosei", JAPAN ENTEROBIOTICS ASSOCIATION, 15 October 2013 (2013-10-15), pages 1 - 6, XP055587706, Retrieved from the Internet <URL:http://www.ejpea.org/shiryo_zip/enterococcus.2013.10.pdf> [retrieved on 20170714] * |
MIAO, J. ET AL.: "Oral administration of fermented milk supplemented with synbiotics can influence the physiological condition of Wistar rats in a dose-sensitive and sex-specific manner", BIOSCI MICROBIOTA FOOD HEALTH, vol. 35, no. 2, April 2016 (2016-04-01), pages 89 - 96, XP055569429, ISSN: 2186-6953 * |
See also references of EP3479835A4 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019230957A1 (ja) * | 2018-06-01 | 2019-12-05 | 雪印メグミルク株式会社 | 筋修復促進用組成物 |
JPWO2019230957A1 (ja) * | 2018-06-01 | 2021-11-04 | 雪印メグミルク株式会社 | 筋修復促進用組成物 |
JP7488182B2 (ja) | 2018-06-01 | 2024-05-21 | 雪印メグミルク株式会社 | 筋修復促進用組成物 |
JP2021042142A (ja) * | 2019-09-06 | 2021-03-18 | 森永乳業株式会社 | 筋肉量及び/又は筋力の維持、或いは筋肉量及び/又は筋力の低下抑制用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物 |
JP7333732B2 (ja) | 2019-09-06 | 2023-08-25 | 森永乳業株式会社 | 筋肉量及び/又は筋力の維持、或いは筋肉量及び/又は筋力の低下抑制用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物 |
WO2022065330A1 (ja) * | 2020-09-23 | 2022-03-31 | 雪印メグミルク株式会社 | 筋委縮予防剤 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2018003900A1 (ja) | 2019-05-16 |
EP3479835A4 (en) | 2020-03-25 |
AU2017287989B2 (en) | 2024-03-14 |
AU2017287989A1 (en) | 2019-02-21 |
EP3479835A1 (en) | 2019-05-08 |
JP6923883B2 (ja) | 2021-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5923238B2 (ja) | 迷走神経活性化剤 | |
AU2011262840B2 (en) | Lipid metabolism-improving agent | |
JP5686680B2 (ja) | 乳酸菌発酵によるカゼイン由来ペプチドの製造方法 | |
JP5888701B2 (ja) | 高タンパク質分解活性を有するラクトバチルス・ヘルベティカス菌 | |
JP6923883B2 (ja) | 栄養状態改善に使用するための組成物 | |
JP6894097B2 (ja) | 腎性貧血改善用組成物 | |
AU2009220403B2 (en) | Agents for promoting secretion and/or suppressing decrease of adiponectin | |
JP5950993B2 (ja) | 迷走神経活性化剤 | |
EP3479836B1 (en) | Cartilage regeneration facilitating composition | |
JP5836928B2 (ja) | 大腸におけるビフィズス菌の増加及び減少抑制剤 | |
AU2015201076B2 (en) | Lipid metabolism-improving agent | |
AU2015200625A1 (en) | Agents for promoting secretion and/or suppressing decrease of adiponectin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17820254 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018525244 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017820254 Country of ref document: EP Effective date: 20190130 |
|
ENP | Entry into the national phase |
Ref document number: 2017287989 Country of ref document: AU Date of ref document: 20170629 Kind code of ref document: A |